鹽酸萬古霉素作用機制 - Medchemexpress - MCE中國

1、Product Data SheetVancomycin hydrochlorideCat. No.: HY-17362CAS No.: 1404-93-9分式: CHClNO分量: 1485.71作靶點: Bacterial; Autophagy作通路: Anti-infection; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 H2O : 33.33 mg/mL (22.43 mM; Need ultrasonic)DMSO : 24 mg/mL (16.1

2、5 mM; Need ultrasonic and warming)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 0.6731 mL 3.3654 mL 6.7308 mL5 mM 0.1346 mL 0.6731 mL 1.3462 mL10 mM 0.0673 mL 0.3365 mL 0.6731 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲

3、存時，請在 1 個內使。體內實驗請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據儲存條件，適當保存；體內實驗的作液，建議您現(xiàn)現(xiàn)配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (1.40 mM); Clear solution此案可獲得 2.

4、08 mg/mL (1.40 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (1.40 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.08 mg/mL (1.40 mM，飽和度未知) 的澄

5、清溶液。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (1.40 mM); Clear solution此案可獲得 2.08 mg/mL (1.40 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活

6、性 Vancomycin hydrochloride于治療細 感染 (bacterial) 的抗素。 它通過抑制易感細 的細胞壁合成的第階段起作。 Vancomycin還改變細胞膜的滲透性并選擇性地抑制核糖核酸的合成。IC & Target Bacterial1體外研究 Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da1. Vancomycin is a uniqueglycopeptide structurally unrelated to any currently availabl

7、e antibiotic. It also has a unique mode of action inhibitingthe second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of speciesof Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans,vi

8、ridans streptococci, enterococci2.體內研究 Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize infusion-relatedadverse effects. Subjects with normal creatinine clearance, vancomycin has an -distribution phase of 30 min to 1 h and a -elimination half-life

9、of 6-12 h. The volume of distribution is 0.41 L/kg. The binding of vancomycin to proteinranges from 10% to 50%. Factors that affect the overall activity of vancomycin include its tissue distribution, inoculumsize, and protein-binding effects1. Vancomycin treatment of infected mice is associated with

10、 improved clinical,diarrhea, and histopathology scores and survival during treatment3.PROTOCOLAnimal Mice: One set of experiments is performed in which infected mice are treated with vancomycin (50 mg/kg) daily for 1,Administration 3 2, 3, or 5 days and are observed for 21 days postinfection or with

11、 vancomycin (20 mg/kg) daily for either 5 or 10 daysand monitoring for 15 days postinfection3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發(fā)表的科研獻 Chemosphere. 2019 Jun;225:378-387. Int J Med Microbiol. 2020 Jan.See more customer validations on H

12、YPERLINK www.MedChemE www.MedChemEREFERENCESPage 2 of 3 www.MedChemE1. Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.2. Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.3. Warren CA, et al. Vancomycin treatments association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficileinfection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96.McePdfHeightCaution: Product